NSE: ALKEM · 1 October 2026 · Dated market coverage
High / Low
₹5,152.00 / ₹5,111.50
Key Takeaways
- ALKEM LABORATORIES LTD. was trading2.24% lowerat ₹5,132.50 and around the middle of the day’s trading range.
- Likely reason:Sector-aligned selling and continuation of recent weakness.
- Cash volume was around2% of the 20-day average full-session volume, so participation remained below an average full session.
Why Alkem Laboratories Shares Are Falling 2.24% Today
Alkem Laboratories Ltd. (ALKEM) fell 2.24% during the trading session, opening at ₹5,139.50 and moving within a tight intraday range between a high of ₹5,152.00 and a low of ₹5,111.50 before settling at ₹5,132.50. Trading volume remained subdued relative to historical averages, showing minimal deviation from typical 5-day and 20-day volume norms.
The broader market and sector indices also experienced mild downward pressure, with the Nifty falling 0.29% and the Nifty Pharma sector benchmark down 0.54%. Alkem’s downward move slightly outpaced the broader pharmaceutical sector correction, contributing to an extended 5-day negative return of 5.32%.
Company-specific news flow recently featured business updates, including the September launch of NeuCeno (cenobamate) for partial-onset seizures and Renocia Exo hair growth serum, alongside management transitions involving the CFO and senior personnel. However, these announcements served as background context rather than direct catalysts for today’s price action.
Likely Reason for Today’s Move
Sector-aligned selling and continuation of recent weakness
No confirmed single catalyst drove today’s decline; the downward price movement aligns with broader sector weakness in pharma stocks and extends a mild recent corrective trend.
- Nifty Pharma sector index declined by 0.54%
- Stock extended its 5-day negative return to 5.32% amid average delivery volumes
Latest Company Developments
Launch of NeuCeno for Seizures
16-Sep-2026
Alkem Laboratories announced the commercial launch of NeuCeno (cenobamate), targeted at treating partial-onset seizures in adult patients. This expansion builds upon the company’s established presence in specialty therapies within the domestic pharmaceutical market. The rollout broadens Alkem’s central nervous system product portfolio.
Introduction of Renocia Exo Hair Serum
08-Sep-2026
The company launched Renocia Exo, described as India’s first patented Ginsenoside Exosome-based hair growth serum. This specialized dermatology product targets the fast-growing aesthetic and hair care segment. It highlights Alkem’s continued focus on differentiated dermatological solutions.
CFO Resignation and Management Changes
24-Sep-2026
Alkem reported the resignation of its Chief Financial Officer, Nitin Agrawal, alongside key changes in senior management personnel. The company appointed Dr. Shubhadeep Sinha as a Senior Management Personnel earlier in the month to bolster operational capabilities. These transitions mark ongoing adjustments to the company’s leadership structure.
Ownership & Transaction Activity
Promoter Pledge / Encumbrance
Promoter Holding
49.70%
51.20% previous qtr
Recent Ownership / Shareholding
FII/FPI
10.42%
10.16% previous qtr
Mutual Funds
16.71%
15.57% previous qtr
Institutional
33.05%
31.56% previous qtr
MF Schemes
29
30 previous qtr
Mutual Fund Holdings
Mutual funds increased their aggregate stake to16.71%from 15.57%in the previous quarter. The number of disclosed MF/UTI shareholders was 29, versus 30 in the previous quarter.
Hdfc Mutual Fund – Hdfc Mid-Cap Fund
5.71M shares • 4.77%
30-JUN-2026
Icici Prudential Multi-Asset Fund
4.27M shares • 3.57%
30-JUN-2026
Sbi Large & Midcap Fund
2.38M shares • 1.99%
30-JUN-2026
Historical Bulk / Block Deals
02 Jun, 2026 • Block
JAYANTI SINHA
12,38,220 shares• ₹5,200.00 • Sell
02 Jun, 2026 • Block
ICICI PRUDENTIAL MUTUAL FUND
9,03,527 shares• ₹5,200.00 • Buy
02 Jun, 2026 • Block
SAMPRADA&NANHAMATI SINGH FAMILY TRUST
5,50,000 shares• ₹5,200.00 • Sell
Large transactions provide ownership/liquidity context and are not directional signals on their own.
What to Watch Next
- Sustained delivery volumes above the 63% average seen recently
- Price stabilization around the 52-week low support near ₹5,051
- Management announcements regarding a replacement for the departing CFO
Frequently Asked Questions
Why is ALKEM LABORATORIES LTD. share price falling today?
No confirmed single catalyst drove today’s decline; the downward price movement aligns with broader sector weakness in pharma stocks and extends a mild recent corrective trend.
How strong is trading participation today?
Participation is moderate rather than exceptional. Volume is about 0.02x the latest 20-day average.
Disclaimer:Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting.
Other Dated Coverage
More Alkem Laboratories news and dated analysis →
Article by: WittyTrades Research Desk
